Laura Loy

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese, Remo Panaccione, Brian G. Feagan et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 70 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +6

Anxiety and Climate Change: A Validation of the Climate Anxiety Scale in a German-Speaking Quota Sample and an Investigation of Psychological Correlates

Marlis Wullenkord, Josephine Tröger, Karen Hamann et al. · 2021 · 55 citations

Social Sciences, Behavioral Sciences, Psychology +9

TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease

Federica Furfaro, Ludovico Alfarone, Daniela Gilardi et al. · Current Drug Targets · 2021 · 39 citations

Life Sciences, Immunology, Pharmacology +17

Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study

Alessandro Pizzocaro, Paolo Colombo, Walter Vena et al. · Endocrine · 2021 · 20 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +9

Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease

Tommaso Lorenzo Parigi, Luca Massimino, Alfredo Carini et al. · Journal of Crohn s and Colitis · 2024 · 19 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +11